COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment

[1]  Jiong Wu,et al.  COX-2 promotes breast cancer cell radioresistance via p38/MAPK-mediated cellular anti-apoptosis and invasiveness , 2013, Tumor Biology.

[2]  W. Sly,et al.  Carbonic Anhydrase IX Promotes Tumor Growth and Necrosis In Vivo and Inhibition Enhances Anti-VEGF Therapy , 2012, Clinical Cancer Research.

[3]  Carme Camps,et al.  microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. , 2011, Cancer research.

[4]  T. Julian,et al.  Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. , 2011, Journal of the National Cancer Institute.

[5]  S. Fox,et al.  The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen , 2011, Breast Cancer Research.

[6]  T. Wilt,et al.  The impact of surgery, radiation, and systemic treatment on outcomes in patients with ductal carcinoma in situ. , 2010, Journal of the National Cancer Institute. Monographs.

[7]  R. Peto,et al.  Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. , 2010, Journal of the National Cancer Institute. Monographs.

[8]  Karla Kerlikowske,et al.  Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. , 2010, Journal of the National Cancer Institute.

[9]  J. Dixon,et al.  Cyclooxygenase-2 Inhibition Does Not Improve the Reduction in Ductal Carcinoma In situ Proliferation with Aromatase Inhibitor Therapy: Results of the ERISAC Randomized Placebo-Controlled Trial , 2010, Clinical Cancer Research.

[10]  S. Fox,et al.  The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy , 2009, British Journal of Cancer.

[11]  S. Fox,et al.  Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Etminan,et al.  Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. , 2008, Journal of the National Cancer Institute.

[13]  W. Loo,et al.  Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[14]  H. Gómez,et al.  Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  W. Jiang,et al.  Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer , 2007, British Journal of Cancer.

[16]  K. Mokbel,et al.  Heterogeneity of ductal carcinoma in situ and its effects on management. , 2006, The Lancet. Oncology.

[17]  S. Fox,et al.  Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Peterse,et al.  Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Emberson,et al.  Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials , 2006, BMJ : British Medical Journal.

[20]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  H. Zou,et al.  Regularization and variable selection via the elastic net , 2005 .

[22]  D. Allred,et al.  Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study , 2004, Modern Pathology.

[23]  S. Swain,et al.  Ductal carcinoma in situ, complexities and challenges. , 2004, Journal of the National Cancer Institute.

[24]  D. Gaffney,et al.  Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy. , 2004, International journal of radiation oncology, biology, physics.

[25]  N. Bundred,et al.  COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ , 2004, British Journal of Cancer.

[26]  T. Hla,et al.  Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Okunieff,et al.  Combination of Radiation and Celebrex (Celecoxib) Reduce Mammary and Lung Tumor Growth , 2003, American journal of clinical oncology.

[28]  M. Dowsett,et al.  Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  M. Steurer,et al.  Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival , 2003, British Journal of Cancer.

[30]  A. Sahin,et al.  Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. , 2002, Cancer research.

[31]  J. Isola,et al.  Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. , 2002, Cancer research.

[32]  D Barnes,et al.  Immunohistochemical detection of steroid receptors in breast cancer: a working protocol , 2000, Journal of clinical pathology.

[33]  M. Brizzi,et al.  p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  James Dignam,et al.  Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial , 1999, The Lancet.